Medical Brief: Treatment of Canine Cutaneous Epitheliotropic T-cell lymphoma with Olacitinib

Medical Brief: Treatment of Canine Cutaneous Epitheliotropic T-cell lymphoma with Olacitinib

Jeylan Aslan, Michael A. Shipstone and Louise M. Sullivan Vet Dermatol. 2021 May 25. doi: 10.1111/vde.12976

This case study reviews the use of olacitinib to treat cutaneous epitheliotropic T-cell lymphoma (CETL).

  • Cutaneous epitheliotropic T-cell lymphoma (CETL) is a rare skin tumor that has a poor prognosis.
  • Treatments with CCNU, PEGylated L-asparaginase, doxil, doxorubicin, retinoids, prednisolone and radiation therapy have been reported.
  • Oclacitinib is a JAK1 inhibitor, but also inhibits JAK2, JAK3, and TYK2
  • Oclacitinib has been shown to deplete CD4+ and CD8+ T cell in vivo as the JAK/STAT pathways are essential for T-cell function.
  • The use of oclacitinib in this dog resulted in a partial remission that lasted for 3 months.
  • The dose of oclacitinib was 0.7 mk/kg twice daily-- a high dose--it is unclear if the low dose approach would have resulted in a similar outcome.
  • The drug and dosage was very well tolerated by this dog.

This is a successful use of a targeted therapy in a dog for a disease other than that which it was initially intended.

It is encouraging to see targeted therapy making a difference in the treatment of canine cancer. To us here at FidoCure®, this strengthens our commitment to using precision medicine and targeted therapy to develop new treatment options to help cancer patients on both sides of the leash.

Dr. Gerry Post

Dr. Gerry Post has been practicing veterinary medicine for over 25 years specializing in veterinary oncology. He currently serves as Chief Veterinary Officer at the One Health Company.

More posts from this author

Great! You've successfully subscribed.
Great! Next, complete checkout for full access.
Welcome back! You've successfully signed in.
Success! Your account is fully activated, you now have access to all content.